Pharmaceutical companies have significantly expanded their research and development (R&D) investments to discover their next item. Five out of five major pharma and biotech companies increased their R&D spending this year compared to the previous year. The top pharmaceutical companies in terms of sales have been investing heavily in R&D to develop new drugs. Yuhan Crop, Celltrion, and Dong-A ST showed a significant increase in R&D expenditures.

According to the Financial Supervisory Service on the 25th, the cumulative R&D investments of 20 major pharmaceutical and biotech companies totaled to KRW 1.867 trillion in Q3, up 14.5% from the KRW 1.6387 trillion in the same period last year. The data was compiled